Medtronic is on track to raise its quarterly dividend per share for the 48th consecutive year, a milestone that positions the company among the longest-running dividend aristocrats in the medical technology sector. Executives have indicated that the board will consider a modest increase in the coming quarters, reinforcing Medtronic’s commitment to returning capital to shareholders. This sustained dividend track record reflects consistent free cash flow generation, which exceeded $6.5 billion in fiscal 2025, and underscores the company’s emphasis on predictable, income-oriented returns for long-term investors.

Two core franchises—Pulsed Field Ablation (PFA) for cardiac arrhythmias and the Symplicity renal denervation system for hypertension—are generating outsized demand. PFA sales grew by 55% year-over-year in the third quarter, driven by new site activations in Europe and Asia, while Symplicity deployments doubled compared with the prior year as clinical uptake accelerated following positive late-stage trial results. Together, these businesses accounted for more than $600 million in revenues in the first nine months of fiscal 2025, contributing to Medtronic’s overall organic growth of 8.3%.

Medtronic maintains an A credit rating from S&P Global Ratings with a stable outlook, reflecting prudent leverage metrics and robust liquidity. As of the end of calendar 2025, the company reported net debt of $26.8 billion and a net leverage ratio of 2.5x adjusted EBITDA, well within its target range of 2.5–3.0x. Management reiterated plans to deploy free cash flow toward strategic M&A—highlighting the $14.5 billion Penumbra acquisition closed last year—while preserving investment-grade status and supporting ongoing share repurchases of up to $3 billion annually.

For fiscal 2026, Medtronic forecasts low- to mid-single-digit organic revenue growth and adjusted diluted EPS growth of 6%–8%, driven by continued uptake in high-growth franchises and operational efficiency initiatives targeting $1.2 billion in cost savings. The company expects to maintain a dividend payout ratio below 50% of adjusted free cash flow, leaving flexibility for bolt-on acquisitions and debt reduction. Investors should weigh the stability of dividend income and credit strength against competitive pressures in core markets and potential pricing reforms in the U.S. healthcare system.